Giampiero de Luca
Directeur/Membre du Conseil chez Auregen Biotherapeutics SA
Profil
Giampiero de Luca is currently a Director at Auregen Biotherapeutics SA, Commave Therapeutics SA, Skylark Bio, Inc., and Stallergenes Canada, Inc. He previously worked as a Director of Intellectual Property at Serono SA from 1988 to 2007 and as a Director at Stallergenes Greer Ltd.
in 2021-2022.
He holds a doctorate degree from the University of Milan.
Postes actifs de Giampiero de Luca
| Sociétés | Poste | Début |
|---|---|---|
Auregen Biotherapeutics SA
 Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | Directeur/Membre du Conseil | - |
| Stallergenes Canada, Inc. | Directeur/Membre du Conseil | - |
Skylark Bio, Inc.
 Skylark Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Skylark Bio, Inc. operates as a biotechnology company. The company is based in Cambridge, MA. | Directeur/Membre du Conseil | - |
Commave Therapeutics SA
 Commave Therapeutics SA Pharmaceuticals: MajorHealth Technology Commave Therapeutics SA is a Swiss pharmaceutical manufacturing company. The private company is based in Geneva, Switzerland. | Directeur/Membre du Conseil | - |
Anciens postes connus de Giampiero de Luca
| Sociétés | Poste | Fin |
|---|---|---|
| STALLERGENES GREER | Directeur/Membre du Conseil | 09/06/2022 |
Serono SA
 Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Corporate Officer/Principal | 17/01/2007 |
Formation de Giampiero de Luca
| University of Milan | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | Technology Services |
Commave Therapeutics SA
Commave Therapeutics SA Pharmaceuticals: MajorHealth Technology Commave Therapeutics SA is a Swiss pharmaceutical manufacturing company. The private company is based in Geneva, Switzerland. | Health Technology |
Skylark Bio, Inc.
Skylark Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Skylark Bio, Inc. operates as a biotechnology company. The company is based in Cambridge, MA. | Commercial Services |
| Stallergenes Canada, Inc. | |
Stallergenes Greer Ltd.
 Stallergenes Greer Ltd. Pharmaceuticals: MajorHealth Technology Stallergenes Greer Ltd. is a healthcare company, which engages in the development and commercialization of allergy immunotherapy products and services. Its products include sublingual products, subcutaneous products, and veterinary products. The company was founded on December 6, 2013 and headquartered in London, the United Kingdom. | Health Technology |